| |
| |
|
| Insider
Information: |
Mammen Mathai |
| Relationship: |
EVP, Pharm, R&D |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
835,695 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$14,499,184 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
835,695 |
|
|
| Total
Value |
$14,499,184 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Innoviva Inc |
INVA |
SVP, Research & Early ... |
2014-08-20 |
334,040 |
|
0 |
Premium* |
|
|
Theravance Biopharma, Inc. |
TBPH |
SVP, Research & Develo... |
2016-03-15 |
288,111 |
|
0 |
Premium* |
|
|
10x Genomics, Inc. |
TXG |
|
2023-06-14 |
171,610 |
2021-06-11 |
0 |
Premium* |
|
|
Johnson & Johnson |
JNJ |
EVP, Pharm, R&D |
2022-02-15 |
41,934 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| JNJ |
Johnson & Johnson |
EVP, Pharm, R&D |
• • – |
2022-02-14 |
4 |
D |
$168.85 |
$394,265 |
D/D |
(2,335) |
37,560 |
0 |
- |
|
| JNJ |
Johnson & Johnson |
EVP, Pharm, R&D |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$558,386 |
D/D |
(3,366) |
41,934 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
|
• • – |
2023-05-11 |
4 |
S |
$52.82 |
$1,743,086 |
D/D |
(33,000) |
169,745 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2014-02-20 |
4 |
D |
$39.98 |
$172,194 |
D/D |
(4,307) |
182,316 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2014-02-14 |
4 |
AS |
$39.26 |
$1,377,688 |
D/D |
(35,000) |
186,623 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2013-05-20 |
4 |
D |
$37.01 |
$121,837 |
D/D |
(3,292) |
202,684 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2013-07-30 |
4 |
AS |
$36.51 |
$255,570 |
D/D |
(7,000) |
211,705 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2013-11-20 |
4 |
D |
$36.40 |
$166,312 |
D/D |
(4,569) |
222,073 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2013-08-20 |
4 |
D |
$35.89 |
$136,849 |
D/D |
(3,813) |
207,892 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2013-04-30 |
4 |
AS |
$33.72 |
$236,164 |
D/D |
(7,000) |
205,976 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2012-08-20 |
4 |
D |
$27.01 |
$125,434 |
D/D |
(4,644) |
207,641 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2014-05-09 |
4 |
D |
$26.86 |
$613,294 |
D/D |
(22,833) |
239,136 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2012-08-13 |
4 |
AS |
$25.68 |
$643,461 |
D/D |
(25,000) |
212,285 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2011-05-20 |
4 |
D |
$25.48 |
$57,203 |
D/D |
(2,245) |
247,137 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2011-02-18 |
4 |
AS |
$23.12 |
$85,567 |
D/D |
(3,701) |
252,622 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2014-08-20 |
4 |
D |
$22.76 |
$74,220 |
D/D |
(3,261) |
334,040 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2010-11-20 |
4 |
D |
$22.52 |
$57,021 |
D/D |
(2,532) |
133,985 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2011-02-20 |
4 |
D |
$22.50 |
$72,900 |
D/D |
(3,240) |
249,382 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2011-11-20 |
4 |
D |
$22.34 |
$50,265 |
D/D |
(2,250) |
245,864 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2013-02-20 |
4 |
AS |
$22.14 |
$154,980 |
D/D |
(7,000) |
212,976 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2013-02-20 |
4 |
D |
$22.10 |
$110,544 |
D/D |
(5,002) |
219,976 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2012-11-02 |
4 |
AS |
$21.42 |
$150,162 |
D/D |
(7,000) |
205,641 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2012-11-20 |
4 |
D |
$21.08 |
$102,744 |
D/D |
(4,874) |
205,928 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2012-05-20 |
4 |
D |
$20.33 |
$77,905 |
D/D |
(3,832) |
237,285 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Development |
• – – |
2015-02-20 |
4 |
D |
$19.52 |
$13,156 |
D/D |
(674) |
227,856 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
